

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS PO Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/529,458	04/13/2000	JAY M. SHORT	DIVER1380-1	5257
7:	590 06/03/2003			
LISA A HAILE GARY CARY WARE & FREIDENRICH 4365 EXECUTIVE DRIVE			EXAMINER	
			KATCHEVES, KONSTANTINA T	
SUITE 1600 SAN DIEGO, CA 92121			ART UNIT	PAPER NUMBER
			1636	30
			DATE MAILED: 06/03/2003	-

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicant(s)		
	Application No.	SHORT, JAY M.	
	09/529,458	Art Unit	
	Examiner	1636	
Action Summary	Konstantina Katcheve	es out with the correspondence	
Office Action	annears on the cover she	et w.	
Office Action Summary The MAILING DATE of this communication To Reply	on appears	F 3 MONTH(S) FRUIVI	
The MAILING DATE OF COLO	DEPLY IS SET TO EXPIRE	apply be timely filed	
A SHORTENED STATUTORY FETAMUNICA A SHORTENED DATE OF THIS COMMUNICA THE MAILING DATE OF THIS COMMUNICA THE MAILING DATE OF THIS COMMUNICA Extensions of time may be available under the provisions of 3: Extensions of time may be available under the provisions of 3: Extensions of time may be available under the provisions of 3: Extensions of time may be available under the provisions of 3: Extensions of time may be available under the provisions of 3: It NO period for reply specified above is less than thirty (30) did after 5: It NO period for reply will the period for reply will reply received by the Office later than three months after 7: Any reply received by the Office later than three months after 7: Any reply received by the Office later than three months after 7: Any reply received by the Office later than three months after 7: Example 1: This action is FINAL. Since this application is in condition closed in accordance with the practice of the provision of Claims Disposition of Claims Claim(s) 16-20 and 22-49 is/are provided in the provision of the provisi	TON. TORN 1 136(a) In no event now you can be applied to a reply within the statutory minimals. The provided will apply and will expire SIX by statute. Cause the application to be a position of the mailing date of this communicate. The mailing date of this communicate and on 17 March 2003. This action is non-first for allowance except for first the under Ex parte Quayle ending in the application. It withdrawn from consideration of the provided withdrawn from consideration of the provided withdrawn from consideration.	um of thirty (30) days will be grained date of this common X (6) MONTHS from the mailing date of	
7) Claim(s) are subject to real are subject to	by the Examiner. s/are: a) accepted or b) any objection to the drawing(s) ion filed on is: a)	approved b) disapproved by the Examiner. Office action.	
12) The oath or declaration is obspaced in the control of the cont	120 of a claim for foreign priority	y under 35 U.S.C. § 119(a)-(d) and the	
a) All Sylving Certified copies of the certified copie	the priority documents have the priority documents have fied copies of the priority do the International Bureau	e been rock occuments have been received in this rock occuments have been received. (PCT Rule 17.2(a)).	
	de of a claim	Notice of Informal Falls	
Attachmentes	CMSA'S CONTRACTOR	1 3 July 1	
Attachmentis: Notice of Draftsperson's Patent Information Disclosure Statemen	otisi Har Garatta ya Maria	ction Summary	
	Ottice Ac		
PTO-326 (Rev. 04-01)			

Art Unit: 1636

DETAILED ACTION

Claims 16-20 and 22-49 are pending in the present application. This Office action is in response to Paper No. 29, filed 17 March 2003 and Paper No. 27, filed 5 December 2003.

Continued Prosecution Application

The request filed on 5 December 2002 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/529458 is acceptable and a CPA has been established. An action on the CPA follows.

Response to Amendment

The rejection of claim 48 under 35 USC §112, first paragraph has been withdrawn in view of Applicant's amendment filed 5 December 2003.

The rejection of claims 16-20 and 22-35 under 35 USC §112, 2nd has been withdrawn in view of Applicant's amendment filed 5 December 2003.

Claims 16-20, 22-33 and 36-45 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view of Short et al (WO 97/04077) and Horikoshi for the reasons already of record.

Claims 16-20, 22-32 and 36-47 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view Stein et al (1996 J. Bact. 178:591-599) and Horikoshi unpatentable over Erickson et al in view of Patanjali et al (1991 Proc. Natl.

Art Unit: 1636

Claims 16-20, 22-33 and 36-45 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view of Short et al (WO 97/04077) and Horikoshi, and further in view of Mendelsohn et al (Curr. Op. in Biotech. 1994 5:482-486.

Response to Arguments

Claims 16-20, 22-33 and 36-45 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view of Short et al and Horikoshi. Claims 16-20, 22-32 and 36-47 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view Stein et al. and Horikoshi, and further in view of Patanjali et al.

Applicant's arguments have been noted; however, they are not found persuasive. The art rejections are maintained as Applicant's arguments are not persuasive. Applicant argues that a prima facie case for obviousness has not been set forth and Erickson et al is deficient as a reference. Applicant's argument regarding the prima facie case for obviousness is similar to that set forth in the amendment field 20 August 2001, which was already addressed and found not persuasive in the rejection mailed 6 November 2001.

Applicant argues that Erickson et al, the primary reference in the art rejections, is deficient. Applicant states that Erickson et al does teach or suggest a molecule from a library generated from a mixed population of organisms and does not teach identification of a third molecule responsible for inhibiting interaction between a first and second molecule wherein all three molecules are encoded by the same nucleic acid source. This is not persuasive as Erickson

e ... interaction between

a first and second molecure whereas a con-

including genomic libraries.

Art Unit: 1636

Generating a library from a mixed population of organisms is taught by both Stein et al and Short et al. Motivation to use the libraries of mixed populations of organisms in the method of Erickson et al. comes both from the prior art, Horikoshi, and from the knowledge of one of ordinary skill in the art. Furthermore, while Erickson et al does not teach that all three interacting molecules are encoded by the same nucleic acid source, the pending claims are not restricted to that embodiment alone. Therefore, this argument is also not persuasive.

Applicant also argues that Patanjuli et al. does not teach normalization as claimed. It is unclear what exactly Patanjuli et al fails to disclose with respect to normalization of a genomic library. According to Applicant's own arguments on page 11 of their reponse, normalization includes at least one of the steps of (1) amplification and (ii) recovery of a fraction of the isolated DNA. Applicant points to US Patent 6,001,574 for this definition of normalization. First, Applicant should note that each patent is examined on its own merits and the disclosure of the cited patent is not dispositive of this point. Second, a flowchart of the steps for producing a normalized library is shown in Figure 1 of Patanjuli et al., which includes fractionating isolated nucleic acids, amplifying single stranded nucleic acids and cloning them into lambda gt10, an expression vector. Therefore, this argument is also not persuasive because Patanjuli et al. does teach amplification.

Claims 16-20, 22-33 and 36-45 also stand rejected under 35 U.S.C. §103(a) as being unpatentable over Erickson et al in view of Short et al. and Horikoshi, and further in view of Applicant argues that the inclusion of Mendelsohn et al. fails to cure the

Mendelsohn is cited for the use of green fluorescent protein as a detectable gene in two hybrid Art Unit: 1636 methods used to find compounds that modulate protein interactions. See p. 485, first column. It is not cited for the a method for the identification of molecule from a library generated from a mixed population of organisms and does not teach identification of a third molecule responsible for inhibiting interaction between a first and second molecule.

Allowable Subject Matter

Claims 34, 35, 46-47 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claism 48 and 49 are allowable.

Conclusion

This is a continuation of applicant's earlier Application No. 09/529458. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action in this case. See MPEP \S 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE NONTHS from the mailing date of this action. In the event a first reply is filed within TWO estion is not mailed until after

the end of the THREE-MONTH smiltered Science - control

An expire on the date the advisory action is mailed, and any extension fee pursuant to a

Art Unit: 1636 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of

Any inquiry concerning this communication or earlier communications from the this final action. examiner should be directed to Konstantina Katcheves whose telephone number is (703) 305-1999. The examiner can normally be reached on Monday through Friday 7:30 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-7939 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-3388.

Konstantina Katcheves May 30, 2003

JAMES KILLEA PHIMARY EXAMINER